SPIRIVA Drug Patent Profile

Which patents cover Spiriva, and when can generic versions of Spiriva launch?

Spiriva is a drug marketed by Boehringer Ingelheim and is included in two NDAs. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has forty-three patent family members in thirty countries.

The generic ingredient in SPIRIVA is tiotropium bromide. There are eight drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the tiotropium bromide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Spiriva

A generic version of SPIRIVA was approved as tiotropium bromide by LUPIN on June 20^th, 2023.

Summary for SPIRIVA

International Patents:	43
US Patents:	1
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	80
Clinical Trials:	110
Patent Applications:	3,917
Drug Prices:	Drug price information for SPIRIVA
Drug Sales Revenues:	Drug sales revenues for SPIRIVA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SPIRIVA
What excipients (inactive ingredients) are in SPIRIVA?	SPIRIVA excipients list
DailyMed Link:	SPIRIVA at DailyMed

See drug prices for SPIRIVA

See drug sales revenues for SPIRIVA

Recent Clinical Trials for SPIRIVA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
GlaxoSmithKline	PHASE4
Fundacio Privada Mon Clinic Barcelona	PHASE4
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	PHASE1

See all SPIRIVA clinical trials

Pharmacology for SPIRIVA

Drug Class	Anticholinergic
Mechanism of Action	Cholinergic Antagonists

Paragraph IV (Patent) Challenges for SPIRIVA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SPIRIVA	Inhalation Powder Capsules	tiotropium bromide	18 mcg	021395	1	2018-05-11

US Patents and Regulatory Information for SPIRIVA

SPIRIVA is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	SPIRIVA	tiotropium bromide	POWDER;INHALATION	021395-001	Jan 30, 2004	AB	RX	Yes	Yes					Y
Boehringer Ingelheim	SPIRIVA RESPIMAT	tiotropium bromide	SPRAY, METERED;INHALATION	021936-001	Sep 24, 2014		RX	Yes	Yes					Y
Boehringer Ingelheim	SPIRIVA RESPIMAT	tiotropium bromide	SPRAY, METERED;INHALATION	021936-001	Sep 24, 2014		RX	Yes	Yes					Y
Boehringer Ingelheim	SPIRIVA RESPIMAT	tiotropium bromide	SPRAY, METERED;INHALATION	021936-002	Sep 15, 2015		RX	Yes	Yes					Y
Boehringer Ingelheim	SPIRIVA RESPIMAT	tiotropium bromide	SPRAY, METERED;INHALATION	021936-001	Sep 24, 2014		RX	Yes	Yes					Y
Boehringer Ingelheim	SPIRIVA RESPIMAT	tiotropium bromide	SPRAY, METERED;INHALATION	021936-001	Sep 24, 2014		RX	Yes	Yes					Y
Boehringer Ingelheim	SPIRIVA RESPIMAT	tiotropium bromide	SPRAY, METERED;INHALATION	021936-001	Sep 24, 2014		RX	Yes	Yes					Y

Expired US Patents for SPIRIVA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Boehringer Ingelheim	SPIRIVA	tiotropium bromide	POWDER;INHALATION	021395-001	Jan 30, 2004
Boehringer Ingelheim	SPIRIVA	tiotropium bromide	POWDER;INHALATION	021395-001	Jan 30, 2004
Boehringer Ingelheim	SPIRIVA	tiotropium bromide	POWDER;INHALATION	021395-001	Jan 30, 2004
Boehringer Ingelheim	SPIRIVA	tiotropium bromide	POWDER;INHALATION	021395-001	Jan 30, 2004
Boehringer Ingelheim	SPIRIVA	tiotropium bromide	POWDER;INHALATION	021395-001	Jan 30, 2004
Boehringer Ingelheim	SPIRIVA	tiotropium bromide	POWDER;INHALATION	021395-001	Jan 30, 2004
Boehringer Ingelheim	SPIRIVA	tiotropium bromide	POWDER;INHALATION	021395-001	Jan 30, 2004

International Patents for SPIRIVA

See the table below for patents covering SPIRIVA around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2479652	MICRONISAT CRISTALLIN DE BROMURE DE TIOTROPIUM (CRYSTALLINE MICRONISATE OF TIOTROPIUM BROMIDE)
Germany	10299026
Poland	2254634
Serbia	88004	INHALACIONI APARAT KOJI SADRŽI INHALACIONI PRAH TIOTROPIJUMA (INHALATION KIT COMPRISING INHALABLE POWDER OF TIOTROPIUM)
Saudi Arabia	1974	ناتج سحق بلوري صغرى الدقائق crystalline micronisate ، عملية لصنعه واستخدامه في تحضير دواء
Egypt	24139	New inhalable powder containing tiotropium
European Patent Office	2254634	INHALATEUR ET FILTRE POUR UN INHALATEUR (INHALER AND SIEVE FOR AN INHALER)

Supplementary Protection Certificates for SPIRIVA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0418716	05C0039	France		PRODUCT NAME: TIOTROPIUM MONOHYDRATE DE BROMURE; NAT. REGISTRATION NO/DATE: NL 31393 20050708; FIRST REGISTRATION: RVG 26191 20011009
0418716	0290010-8	Sweden		PRODUCT NAME: TIOTROPIUM, 3BETA-(DI(2-TIENYL)HYDROXIACETOXI)-6BETA,7BETA-EPO XI-8METYL-1ALFAH,5ALFAH-TROPANIUM, ELLER ETT SALT DAERAV; NAT. REGISRTATION NO/DATE: 18094 20020503; FIRST REGISTRATION: NL RVG 26 191 20011009
0418716	SPC/GB02/036	United Kingdom		PRODUCT NAME: SCOPINE DI-(2-THIENYL)GLYCOLATE IN THE FORM OF THE QUATERNARY SALTS - ESPECIALLY SALTS OF TIOTROPIUM - PREFERRED TIOTROPIUMBROMIDE AND TIOTROPIUMBROMIDE MONOHYDRATE; REGISTERED: NL RVG26191 20011009; UK PL14598/0062 20020514
0418716	C300084	Netherlands		PRODUCT NAME: ZOUTEN VAN TRIOTROPIUM, IN HET BIJZONDER TIOTROPIUM BROMIDE; REGISTRATION NO/DATE: RVG 26191 20011009
0418716	300084	Netherlands		PRODUCT NAME: ZOUTEN VAN TRIOTROPIUM, IN HET BIJZONDER TIOTROPIUM BROMIDE; REGISTRATION NO/DATE: RVG 26191 20011009

Market Dynamics and Financial Trajectory for SPIRIVA (Tiotropium Bromide)

Last updated: January 17, 2026

Executive Summary

SPIRIVA (tiotropium bromide) remains a cornerstone medication in the management of chronic obstructive pulmonary disease (COPD) and asthma. As one of the most prescribed inhaled bronchodilators worldwide, it commands a significant share of the respiratory therapeutics market. This analysis explores the current market dynamics, growth drivers, challenges, and the financial trajectory of SPIRIVA. It highlights competitive positioning, regulatory influences, and future growth prospects amid evolving healthcare policies and technological advancements.

---

What Are the Market Drivers for SPIRIVA?

Increasing Prevalence of COPD and Asthma Globally

• Global COPD prevalence is projected to reach 550 million cases by 2030, with significant burdens in Asia-Pacific, Europe, and North America.[1]
• Asthma affects over 339 million people worldwide, driving demand for inhaled therapies such as SPIRIVA.[2]

Aging Population

• The elderly population (>65 years) drives demand due to increased respiratory comorbidities.
• The aging demographic constitutes approximately 9% of the global population in 2022, expected to grow to 16% by 2050, boosting long-term prescriptions.[3]

Advancements in Inhalation Devices

• Development of DPI (dry powder inhalers) with user-friendly designs increases adherence and expands market reach.
• SPIRIVA's proprietary HandiHaler and Respimat devices contribute to sustained demand.

Expanding Therapeutic Indications

• Originally approved for COPD, recent approvals extend its use to asthma maintenance in certain age groups, broadening the target patient base.[4]

Summary Table: Key Market Drivers

Driver	Impact	References
COPD & Asthma prevalence	Increase drug utilization	[1], [2]
Aging populations	Long-term therapy growth	[3]
Device innovation	Improved adherence, increased prescriptions	N/A
New therapeutic indications	Broader market access	[4]

---

What Are the Challenges and Barriers Impacting SPIRIVA’s Market?

Patent Expiry and Generic Competition

• The original patent expired in 2019 in many jurisdictions, leading to introduction of generic tiotropium products.
• Generics typically offer lower prices, pressuring the pricing power of brand-name SPIRIVA.

Price Pressures and Reimbursement Policies

• Healthcare payers increasingly favor cost-effective therapies, impacting revenues.
• Reimbursement reforms in the US (Medicare and Medicaid policies) and Europe dictate reimbursement rates, influencing sales volume.

Competitive Landscape

Competitors	Key Products	Market Share (Estimate)	Notes
Boehringer Ingelheim	Spiriva (original)	~70% in COPD market	Dominant for over a decade
Mylan (Viatris) / Teva	Generic Tiotropium inhalers	Growing	Price-sensitive segment
AstraZeneca	Anoro Ellipta, Breztri Aerosphere	Diversification	Competitors targeting similar indications

Regulatory and Reimbursement Uncertainties

• Stringent approval processes for biosimilars or generics.
• Variations in reimbursement policies across countries affecting sales.

Summary Table: Market Barriers

Barrier	Effect	Sources
Patent expiry	Increased generic competition, price erosion	[5], [6]
Reimbursement policies	Impact on prescribing practices and access	[7], [8]
Competitive products	Market fragmentation and lower market share for SPIRIVA	N/A

---

How Does the Financial Trajectory of SPIRIVA Evolve?

Revenue Trends

• Pre-Patent Loss: SPIRIVA’s peak global revenues reached approximately €2.56 billion in 2017.[9]
• Post-Patent Expiry: Revenues declined by approximately 15-20% annually post-2019 due to generic competition.
• Current Status (2022): Estimated revenues are approximately €1.2 billion, with a gradual stabilization as biosimilars penetrate markets.

Market Segmentation and Geographic Distribution

Region	2022 Revenue Share	Remarks
Europe	40%	Largest market; reform measures affect uptake
North America	30%	Growing base; reimbursement favorable
Asia-Pacific	20%	High growth potential; emerging middle class
ROW (Rest of World)	10%	Increasing access, but pricing and reimbursement barriers

P&L and Investment Trends

• Research & Development (R&D): Investment in combination products and new delivery systems.
• Partnerships: Strategic alliances for biosimilar development to mitigate revenue decline.
• Pricing Strategy: Transition towards value-based pricing, especially in mature markets.

Forecasting the Financial Trajectory (2023–2027)

Year	Estimated Revenue	Growth Rate	Key Factors
2023	€1.0 - 1.2 billion	Stable to slight decline	Competition, biosimilars, regulations
2024	€1.0 billion	Flat to slight growth	New formulations, expanded indications
2025	€1.1 billion	5% growth	Market expansion, new markets
2026	€1.2 billion	10% growth	Biosimilars adoption, pipeline products
2027	€1.3 billion	8% growth	Persistent demand, innovation-driven

Strategic Responses

• Diversification: Expanding into combination therapies (e.g., tiotropium/olodaterol).
• Innovation: Developing improved inhaler devices to enhance adherence.
• Global Access: Penetrating emerging markets with cost-effective formulations.
• Regulatory Navigation: Accelerating approvals for indications such as asthma in pediatric populations.

---

How Do Regulatory Policies Shape the Market?

Major Regulatory Agencies Impacting SPIRIVA

Agency	Recent Policies Impacting Market	Dates & Notes
FDA (US)	Guidance on biosimilar pathways; incentives for inhaled therapies	Draft guidance 2021, finalized in 2022
EMA (EU)	Post-patent expiry policies favoring generics and biosimilars	Revisions 2020-2022
PMDA (Japan)	Accelerated approval pathways for respiratory medications	Ongoing policy adaptations

Regulatory Trends

• Encouragement of Biosimilar Entry: Facilitates cost reduction but intensifies competition.
• Preference for Value-Based Reimbursement: Pushes companies to demonstrate cost-effectiveness.
• Orphan and Rare Disease Designations: Limited applicability for SPIRIVA but incentivizes innovation.

---

How Does Competition Shape the Future of SPIRIVA?

The Rise of Biosimilars and Generics

Name	Approval Status	Market Impact	Approximate Launch Year
Tiotropium (generic)	Approved in Europe, US (by certain manufacturers)	Price erosion, volume growth	2019–2022
HandiHaler & Respimat	Proprietary devices, brand loyalty	Sustained niche for premium devices	Continuous

Emerging Therapeutics and Technologies

Innovation	Potential Impact	Status
Fixed-dose combinations	Enhance adherence, expand indications	Under development
Digital inhaler monitoring	Improve medication adherence, real-time data collection	Pilot programs in key markets
Novel delivery devices	Better drug deposition, reduced side effects	Clinical trials ongoing

How Will Future Competition Reshape Market Share?

• Generics will continue to erode SPIRIVA’s premium pricing.
• Innovative combination inhalers may capture larger market segments.
• Digital health solutions could redefine patient engagement and adherence metrics.

---

Key Takeaways

• SPIRIVA remains a dominant inhaled bronchodilator, vital for COPD and asthma management, though facing headwinds from patent expiry and generics.
• Market growth hinges on demographic trends, technological innovations, and expanding indications, especially in emerging markets.
• Revenue is forecasted to stabilize at around €1.2 billion by 2023, with a trajectory towards gradual growth driven by pipeline and market expansion strategies.
• Competitive pressures necessitate continuous innovation, strategic alliances, and value-based pricing to sustain market relevance.
• Regulatory policies favor biosimilar proliferation, intensifying competition but also providing opportunities for differentiated delivery systems.

---

FAQs

Q1: How has patent expiry affected SPIRIVA’s market share?
Patent expiry in 2019 led to the introduction of generic tiotropium products, causing a decline in brand revenues by approximately 15-20% annually through 2022, though proprietary device and brand loyalty sustain premium segments.

Q2: What are the primary growth opportunities for SPIRIVA?
Key opportunities include expanding into emerging markets, developing combination therapies, leveraging digital adherence tools, and extending indications to pediatric asthma.

Q3: How do biosimilars impact SPIRIVA’s market?
Biosimilars increase price competition, leading to volume-driven revenue growth but pressure on profit margins. The success of biosimilar penetration depends on regulatory approval and payer acceptance.

Q4: What role do technological innovations play in SPIRIVA’s future?
Innovations such as improved inhaler devices and digital monitoring enhance adherence, improve patient outcomes, and provide strategic differentiation against generic competitors.

Q5: Are regulatory policies favoring or hindering SPIRIVA’s market expansion?
While regulatory agencies facilitate biosimilar approval, policies favoring cost containment and biosimilar substitution pose challenges for the brand-name drug, necessitating strategic adaptation.

---

References

1. World Health Organization. "Global Surveillance, Prevention and Control of Chronic Respiratory Diseases." WHO Report, 2021.
2. Global Initiative for Asthma (GINA). "Global Strategy for Asthma Management and Prevention," 2022.
3. United Nations, Department of Economic and Social Affairs. "World Population Ageing," 2022.
4. Boehringer Ingelheim. "SPIRIVA approvals and indications," 2022.
5. European Medicines Agency. "Biosimilar medicines policy," 2021.
6. U.S. Food and Drug Administration. "Draft Guidance on Biosimilar Development," 2021.
7. National Health Service (UK). "Reimbursement policies for respiratory drugs," 2022.
8. Centers for Medicare & Medicaid Services. "Reimbursement updates," 2022.
9. Boehringer Ingelheim Annual Report. "Financial Highlights," 2017.